SNAP 94847 (SNAP-94847) is a selective and competitive MCH1 receptor (MCH1-R) antagonist (Ki: 2.2 nM). It has anxiolytic and antidepressant activity and reduces food intake in mice.

MCH1 receptor:2.2 nM (Ki, cell free)

SNAP-94847表现出了对MCH1受体的亲和力（Ki: 2.2 nM）以及对人类R1A受体（>80倍）和D2受体（>500倍）的选择性优势[1]。

SNAP-94847（10 mg/kg，口服）对2小时内测量的基础水消耗量没有影响：对照组（2.0 mL）、16g处理组（2.3 mL）。MCH诱导的饮水量被SNAP-94847在1.0、2.5和10 mg/kg的剂量下显著抑制[1]。连续21天以fluoxetine或SNAP 94847（每日20 mg/kg）处理的BALB/c小鼠显示出在quinpirole诱导的运动活动增加方面有明显提升，且在使用SNAP 94847后，超动力出现的时间点比fluoxetine早。无论哪种化合物，连续使用7天也足以增强BALB/c小鼠对quinpirole的反应[2]。黑素集中激素的脑内及脑室内注射，以及皮质醇的长期注射，增加了强迫游泳测试中的不动时间，并降低了蔗糖偏好测试中的蔗糖偏好。所有这些抑郁样行为都被SNAP-94847的蓝斑微量注射所逆转[3]。

Chronically treated Sprague–Dawley rats were administered fluoxetine (18 mg/kg/day) or SNAP 94847 (20 mg/kg/day) via oral gavage in 20% beta-cyclodextrin for 2 weeks (1 injection, 6 h into light cycle). For acute treatment, drugs were given orally in 20% betacyclodextrin 1 h before testing. On each test day, locomotor activity was recorded during a 60 min habituation to the novel locomotor cage, after which the rats were administered quinpirole (0.3 mg/kg, i.p.) and returned immediately to the cage, where locomotor activity was measured for an additional 180 min. In each case-control animals were administered the corresponding vehicle, without drug [2].